Table 3.
The results of statistical analysis
| Parameter | Patients, n | For OS | For PFS | ||
|---|---|---|---|---|---|
| p-value, log-rank | Hazard ratio (CI 95%) | p-value, log-rank | Hazard ratio (CI 95%) | ||
| PET/CT-parameters | |||||
| SUVmax > 4 | 20/36 | 0.014 | 3.19 (1.2–8.48) | 0.002 | 3.01 (1.39–6.51) |
| n, FLs ≥ 1 | 23/36 | 0.10 | 2.29 (0.83–6.32) | 0.08 | 1.86 (0.88–3.93) |
| n, FLs > 3 | 15/36 | 0.003 | 3.7 (1.48–9.27) | < 0.001 | 5.54 (2.25–13.6) |
| EMD Present versus not present | 12/36 | 0.004 | 3.40 (1.39–8.30) | 0.006 | 2.67 (1.23–5.83) |
| n, FLs > 3 on CT only* | 28/36 | 0.74 | 1.19 (0.39–3.59) | 0.54 | 1.31 (0.53–3.22) |
| Remission status | |||||
| PR or worse versus at least vgPR | 21/36 | 0.327 | 1.58 (0.63–3.97) | 0.376 | 1.38 (0.67–2.83) |
| Prior therapy lines | |||||
| ≥ 2 | 23/36 | 0.265 | 1.76 (0.64–4.87) | 0.128 | 1.84 (0.83–4.07) |
| ≥ 3 | 14/36 | 0.72 | 2.2 (0.91–5.4) | 0.001 | 3.6 (1.59–8.13) |
| Clinical parameters | |||||
| Age (≥ 65 years) | 11/36 | 0.169 | 1.86 (0.75–4.58) | 0.082 | 1.87 (0.86–4.07) |
| Elevated LDH (> 250 U/l) | 20/36 | 0.006 | 3.86 (1.38–10.77) | 0.003 | 2.89 (1.35–6.17) |
| ISS-Stage (I vs. II vs. III) | 19/13/4 | 0.016 | 2.37 (1.26–4.44) | 0.046 | 1.88 (1.09–3.24) |
The statistically significant results with p-value below 0.05 are highlighted in bold
OS overall survival, PFS progression free survival, SUV standardized uptake value, FLs focal (bone) lesions, EMD extramedullary disease, PR partial remission, vgPR very good partial remission, FLC free light chains. *Over 3 bone lesions on CT without PET-positivity